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ABSTRACT 
 
 Ependymin (EPN) is a goldfish neurotrophic factor (NTF) that is one of the most 
abundant secreted glycoprotein components of brain extracellular fluid (ECF) and 
cerebrospinal fluid.  This protein was first discovered due to its enhanced turnover 
following learning events, but has since been found to function in other important cellular 
events such as long-term memory formation and optic nerve elongation (Shashoua, 1976; 
Shashoua, 1977; Shashoua, 1985).  Goldfish EPN has several demonstrated effects on 
mammalian cells, and immuno-reactive EPN-like proteins have been observed in a 
variety of organisms ranging from invertebrates (Limulus) to mice. 
 Some NTFs have been shown to alleviate oxidative stress, one of the primary 
mediators of cell damage in neurodegenerative conditions.  One mechanism by which 
they accomplish this is to increase cellular levels of anti-oxidative enzyme superoxide 
dismutase (SOD).  In fact, our lab recently showed that a synthetic EPN fragment (CMX-
8933) increases SOD mRNA and protein levels in rat primary cortical cultures (Parikh, 
2003).  Transgenic mice and rabbits that overexpress SOD are resistant to ischemia, 
while mice that lack SOD present with worse ischemic damage.  Thus, due to this 
important SOD activating NTF-like feature of EPN may have potential therapeutic 
applications for treating neurodegenerative conditions such as Alzheimer’s disease, 
Parkinson’s or stroke. 
 Because full-length NTFs do not efficiently cross the blood brain barrier (BBB) 
when administered intravenously, our lab, in collaboration with Ceremedix, Inc. (Boston, 
MA), is interested in designing short peptides that mimic the action of full-length NTFs, 
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especially EPN.  Due to proteases that naturally exist in ECF, EPN is partially cleaved to 
release the 8 aa peptide KKETLQFR.  Other brain proteins, like encephalins and 
endorphins, also release similar short active components, so we hypothesized that this 8 
aa peptide may represent an active component of EPN.  Indeed, our lab demonstrated that 
administration of this sequence in synthetic form (termed CMX-8933) to rat primary 
cortical cells increases cellular titers of SOD (Parkih, 2003). 
 This thesis was divided into three parts.  The first part investigated which signal 
transduction pathway is responsible for CMX-8933’s ability to upregulate SOD.  Because 
our lab also showed that CMX-8933 activates the MAPK pathway (Hasson, 1998; El-
Khishin, 1999; Adams et al., 2003) we hypothesized that CMX-8933 may use this 
pathway to upregulate SOD.  Inhibition experiments were performed to test three known 
components of the MAPK pathway, and a member of an unrelated pathway.  Six 
independent  SOD immunoblot experiments demonstrated that pre-treatment of rat 
primary cortical cultures with specific inhibitors for the protein kinase-C family (PKC), 
protein tyrosine kinases (PTKs), or MEK protein kinases (MEKK), completely blocked 
(p = 0.0001) CMX-8933’s average 15-fold upregulation of SOD.  Thus, these three 
critical components of the MAPK pathway appear to be involved in the CMX-8933-
induced upregulation of SOD.  An inhibitor of transcription factor NF-κB in an unrelated 
pathway had no significant effect (p =  0.901). 
 The second part of this thesis tested whether treatment of rat primary cortical 
cultures with CMX-8933 increases the cellular titers of mRNAs related to translation.  
Previous observations indicated that treatment of these cells with with CMX-8933 
induces neurite sprouting (Shashoua, unpublished), and that EPN plays a role in optic 
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nerve elongation (Schmidt and Shashoua, 1988), two processes related to growth.  So we 
hypothesized that EPN, or CMX-8933, may stimulate the transcriptioin of mRNAs 
related to growth.  We tested mRNAs for translation factor EF-2, and ribosomal proteins 
S12 and L19 based on previous observations in our lab with hybridization arrays (Parikh, 
2003).  RT-PCR experiments indicated that treatment of rat primary cortical cultures with 
10 ng/ml CMX-8933 for 5 hrs increased the mRNAs for S12 an average of 12-fold 
relative to untreated cultures (N = 3, p = 0.02), L19 an average of 9-fold (N = 3, p = 
0.048), and EF-2 an average of 11-fold (N = 3, p = 0.045).  Levels of housekeeper 
polyubiquitin remained unchanged.  Thus 3 gene products related to growth are indeed 
upregulated by CMX-8933. 
 The third part of this thesis investigated the SOD stimulatory effects of full-length 
EPN versus its cleavage product CMX-8933.  Previous studies showed that full-length 
NTFs BDNF and NGF upregulate SOD in neuronal cells.  Because CMX-8933 
upregulates SOD, maybe full-length EPN does too.  We hypothesized that if CMX-8933 
represents the receptor-binding domain of full-length EPN, that full-length EPN may 
show the same stimulatory effects as CMX-8933, and may upregulate SOD.  
Extracellular fluid (ECF) was prepared from goldfish brains, the traditional source for 
isolating EPN.  Analysis of the ECF on protein gels demonstrated the presence of a 
complex protein pattern dominated by two bands at 37,000 and 31,000 daltons, the 
known sizes of EPN-β (glycosylated) and EPN-γ (non-glycosylated), respectively.  
Immunoblots performed with EPN antibody “Sheila” (directed against the C-terminal end 
of EPN, Shashoua and Moore, 1978) confirmed the identity of these two ECF bands as 
EPN.   Cultured mouse Nb2a neuronal cells were treated in six independent experiments 
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with 12 µg/ml ECF protein for 5 hrs, and whole cell lysates were tested for levels of SOD 
by immunoblots.  This ECF treatment of neuronal cells produced a mean 4-fold increase 
in SOD levels (p = 0.007), supporting our hypothesis. 
 However, since ECF is a complex mixture, this data did not show which ECF 
component was resonsible for the SOD signal.  Since ECF is known to contain CMX-
8933 EPN cleavage product, which by itself can upregulate SOD, it is possible CMX-
8933 was responsible for the signal, not full-length EPN.  To address this issue, 
microdialysis was performed using an 8,000 dalton MWCO membrane to remove low 
MW components from the ECF (including CMX-8933, MW = 1149), leaving EPN-β 
(MW 37,000) and EPN-γ (MW 31,000) present in the dialyzed ECF.  Four independent 
experiments indicated no significant difference (p = 0.116) between dialyzed versus non-
dialyzed ECF for activating SOD.  Thus, CMX-8933 does not appear to be responsible 
for ECF’s ability to increase SOD, but instead, high MW molecules (including full-length 
EPN) appear to be the active components.  Altogether, the data from this thesis extends 
our knowledge of the mechanism of action of both full-length EPN and its cleavage 
product CMX-8933. 
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BACKGROUND 
 
Neurotrophic Factors 
 Neurotrophic factors (NTFs), a subclass of growth factors, are naturally occurring 
brain glycoproteins that regulate both the survival and growth of various populations of 
neurons in the central and peripheral nervous system.  Recent research shows that NTFs  
have an additional role in synaptic plasticity (Wu and Partridge, 1999; Nishi, 1994; Stahl, 
2003). 
  NTFs can be divided into four categories: neurotrophins, such as brain-derived 
neurotrophic factor (BDNF) and nerve growth factor (NGF), the neuropoietic cytokines, 
the fibroblast growth factors (FGF), and the glial-derived growth factors (GDNF) (Jehan 
et al., 1996; Cui et al., 1998; Bear et al., 2001; Stahl, 2003).  The members of these NTF 
families demonstrate 50% or more homology, and have affinities for particular classes of 
receptors.  Neurotrophins, in particular, act at specific cell surface receptors. Most of 
these receptors are neurotrophin-activated protein kinases, called trk receptors (Bear et 
al., 2001). In addition to receptor interaction with ligand, neurons use many routes for 
internalization of these factors (Figure 1).  They may acquire NTFs by target-derived 
acquisition (from their target tissue, whether neuronal or non-neuronal), by pancrine 
acquisition (neighboring neurons and other cells), or by autocrine acquisition.   
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Figure 1: General Mechanism of Neurotrophic Factors (Kibiuk, 1994). 
 
The survival and differentiation of neurons is mainly regulated by target-derived 
neurotrophic factors.  In this cell survival model, developing neurons that fail to make 
correct connections will be deprived of necessary NTFs and die, whereas neurons that 
establish correct connections survive, differentiate and mature (Connor and Dragunow, 
1998; Bear et al., 2001; Stahl, 2003). 
 
Role of NTFs in Stroke Therapy 
 One of the most important roles that NTFs have is their ability to help diminish 
the destructive neuronal oxidative stress associated with stroke.  A variety of NTFs have 
been shown to converge on damaged tissue following stroke (Ferrer et al., 1998) 
however, the NTFs that are best characterized relative to stroke are BDNF and GDNF.  
They have exhibited therapeutic effects in the brain, especially in the case of ischemic 
stroke.  BDNF is known for promoting the survival and growth of various nerve cells, 
and has neuroprotective effects when administered in vivo (Wu and Partridge, 1999; 
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Ferrer et al., 2001).  GDNF is well known for its protection and rescue of dopaminergic 
neurons in Parkinson’s Disease; however, it also provides protection for other neuronal 
motor neurons and peripheral ganglia in hypoxia-induced brain injury (Ikeda et al., 
2000).   
 Although the systemic administration of full-length NTFs has shown some 
therapeutic activities, the main problem lies with the ability to physically deliver these 
beneficial neuroprotective NTFs to the brain.  The first obstacle is the brain capillary wall 
called the blood brain barrier (BBB), that the NTFs cannot efficiently penetrate.  
Therefore, NTFs need to be coupled with a BBB drug delivery system.  The second 
obstacle is that NTFs have a rapid rate of removal from the blood, mainly by the liver 
(Wu and Partridge, 1999).  These problems will be addressed later in more detail. 
 
Ependymin 
Ependymin (EPN) is a secreted glycoprotein component of the extracellular and 
cerebrospinal fluids of the goldfish brain.  This protein was first discovered in goldfish 
brains due to its enhanced turnover rates after learning events (Shashoua, 1976; Shashoua 
1977).  At first, EPN was thought to be located only in the central nervous system, 
localized in the ependymal zone from which it derives its name (Benowitz and Shashoua, 
1979), however later evidence found that it was also detected as a novel secretory protein 
in the brain extracellular fluid (Shashoua, 1985).   
Ependymin exists in two forms, β and γ (MW 37,000 and 31,000, respectively).  
Ependymin β is glycosylated, and ependymin γ is non-glycosylated (Shashoua, 1976; 
Shashoua, 1985; Konigstorfer et al., 1989; Shashoua et al., 1990).  The protein portion 
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consists of 216 amino acid residues, including two N-glycosylated sites.  Both proteins 
can bind concanavalin A and can be isolated from the brain extracellular fluid by lectin 
affinity chromatography (Schmidt and Shashoua, 1983).  
Preparations of ECF proteins from goldfish brains were found to contain 
proteases and esterases (Shashoua and Holmquist, 1986).  Protease activity present in the 
ECF of goldfish brains (Schmidt and Shashoua, 1983; Shashoua, 1985; Shashoua, 1988) 
promotes the proteolysis of ependymin, releasing specific smaller peptides into the ECF 
(Shashoua, unpublished).  This result indicates that ependymin might exert its biological 
activity in vivo via smaller polypeptide fragments.  EPN β and γ were shown to constitute 
14% of the total protein content of the brain extracellular fluid, and also a minor 
component of the serum proteins (0.3%) (Schmidt and Shashoua, 1981; Schmidt and 
Lapp, 1987).    
 
Ependymin’s Function 
EPN is a multi-functional protein.  A variety of cellular actions are common 
between EPN and other complex NTFs, such as involvement in synaptic biochemical 
changes associated with long-term memory consolidation, optic nerve elongation, and 
neuronal growth (Shashoua and Moore, 1978; Schmidt, 1987; Piront and Schmidt, 1988; 
Schmidt et al., 1995; Schmidt, 1995).  Injection of anti-EPN Ab can block memory 
formation (Schmidt and Shashoua, 1988; Adams and Shashoua, 1994).  In addition, EPN 
has been linked with learning (Shashoua, 1985; Piront and Schmidt, 1988; Shashoua and 
Hesse, 1989; Rother et al., 1995), acclimation to the cold (Tang et al., 1999), optic nerve 
regeneration and neuroplasticity (Shashoua, 1985; Schmidt and Shashoua, 1988; 
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Shashoua, 1988; Shashoua, 1991), and neuronal growth (Schmidt and Shashoua, 1988; 
Schmidt et al., 1991).   
 
Ependymin Peptide Therapy: CMX-8933 
 Because full-length NTFs inefficiently cross the BBB, our laboratory in 
collaboration with Ceremedix Inc. (Boston) is currently investigating small peptide 
mimetics of EPN as potential therapeutics for stroke.  Peptide CMX-8933 (KKETLQFR), 
corresponding to positions 78-85 in the mature EPN sequence (see Figure 2), was used as 
a potential mimetic of EPN (Shashoua et al., 2001).  This sequence was chosen because 
its 6-amino acid C-terminal portion (ETLQFR) is reproducibly generated when pure EPN 
is incubated with trypsin (Shashoua, 1991), or goldfish ECF (Shashoua, unpublished), 
and protease cleavage consensus sites exist nearby (Adams et al., 1996).      
 
 
Figure 2: Full-length Ependymin Sequence and Rationale for Design of Therapy Peptide CMX-8933.  
The completely conserved 8 amino acid peptide drug sequence, represented in the box, is a proteolytic 
cleavage product of the 215 amino acid sequence of full-length EPN, both present in ECF.  Charged amino 
acids are indicated by ‘+’ or ‘-’above sequence (Adapted from Adams et al., 1995; Adams et al., 2003). 
 
Also, the sequence is completely conserved among the six deduced protein 
sequences of the only true (highly homologous)-epn genes sequenced to date from the 
order Cypriniformes (Adams and Shashoua, 1994; Adams et al., 1996).  Our working 
hypothesis is that  peptide CMX-8933 may be a biologically active proteolytic cleavage 
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product of EPN in the ECF (where EPN is present as well) possibly comprising EPN’s 
receptor-binding domain.  Encephalins and endorphins serve as a precedent for the 
proteolytic removal of functional byproduct fragments (Goldstein, 1976). 
 
DHA as a BBB-Carrier: Protarga, Inc. 
 Protarga, Inc, a clinical stage pharmaceutical company located outside of 
Philadelphia, Pennsylvania, focuses on linking well characterized drugs to BBB carrier 
DHA to facilitate delivery into the brain, and other tissues.  The principal areas of interest 
are: oncology, central nervous system disorders, and infectious diseases.  The company, 
co-founded by Victor Shashoua, utilizes fatty acid technology to develop Targaceutical® 
compounds that consist of known therapeutic agents attached to fatty acids (Protarga 
Homepage, 2003).  This technology is based on previous findings that the fatty acid 
docosahexaenoic acid (DHA) has hydrophobic properties that allow it to cross the Blood 
Brain Barrier (BBB).  DHA is a naturally occurring fatty acid that is 22 carbons long with 
six double bonds, and is a primary fatty acid component of synaptic endings, which is 
necessary for brain development (Shashoua and Hesse, 1996).  Protarga uses DHA as the 
carrier molecule for several therapeutic drugs they want to deliver to the brain.  The 
resulting Targaceutical® drugs are designed to improve pharmacological performance by 
delivering more drug to a specific location for an extensive period of time, while 
maintaining the overall safety profile of the original well characterized product (Protarga 
Homepage, 2003). 
 Protarga has developed three main drugs, Taxoprexin, Doprexin, and 
Clozaprexin.  All are currently being tested in both animal and human trials.  It's lead 
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Targaceutical® product is Taxoprexin®, taxol (paclitaxel) linked to DHA, which is used 
in the treatment of certain cancers. DHA-paclitaxel, the active ingredient in Taxoprexin®, 
has already advanced through Phase I human clinical trials, and is now in Phase II human 
clinical trials (Protarga Homepage, 2003).  Doprexin, or NMI-8739, consists of dopamine 
linked to DHA, and is used to transport dopamine to the brain to treat Parkinson’s disease 
patients (Shashoua and Hesse, 1996).  NMI-8739 has been found to increase dopamine 
uptake in the brain by more than 10-fold in animal models (Shashoua et al., 2001).  
Clozaprexin is a combination of clozapine, one of the most potent anti-psychotic 
substances known, and DHA.  It is used to treat a variety of psychotic diseases, such as 
schizophrenia, by transporting clozapine across the BBB using DHA as the carrier.  
Clozaprexin has been found to be ten times more potent and longer lasting than clozapine 
alone (Baldessarini et al., 2001). 
 
Adams Lab Contributions to NTF Research to Date 
 In collaboration with Ceremedix Inc., numerous WPI students have contributed to 
the research involving EPN.  The earliest work began in 1994 with the isolation of  
goldfish epn genes (Adams and Shashoua, 1994), with the ultimate goal of cloning full-
length human epn. After that, in an effort to walk up the evolutionary ladder, two more 
species were cloned in 1996 (Adams et al., 1996).  
Research related to small peptide mimetics of EPN started in 1998, when a 
Master’s student demonstrated that ependymin-like therapy peptides NMI-9236 and 
NMI-8933 activate AP-1 transcription factor in mouse neuroblastoma NB2a cells 
(Hasson, 1998).  Sleeper (1999) engineered C-127 cells, an alternative cell culture based 
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in vitro production system, to secrete 8933 and 9236.  Transfection experiments by the 
late Adam El-Khishin demonstrated that the AP-1 activated by NMI-9236 and NMI-8933 
administered to NB2a cells is indeed a functional particle (El-Khishin, 1999).  In 2000, 
further research confirmed El-Khishin’s findings, and demonstrated that anti-oxidative 
enzymes are upregulated by 9236 and 8933 therapy peptides (LeBlanc, 2000).   
Then in 2001, our lab demonstrated that peptide conjugated to DHA carrier more 
efficiently upregulated SOD in the brain (Pfeiffer et al., 2001).  Later that year, CMX-
204-36 was also determined to upregulate SOD, GPX, and CAT in the brain of a rat 
(Armistead, 2001).   
  More recently, studies in 2002 found that peptides CMX-204-16, when 
compared to CMX-115-2, increased the cellular titer of SOD protein, as well as peptides 
CMX-204-75, CMX-207-07, CMX-115-9 (Luiz et al., 2002).  In addition, in 2003 the 
data indicated that peptides 115-2, 115-9, 2115 and 8933 are able to increase the total 
cellular levels of SOD by as much as 14.0 fold, that SOD is a part of the cell’s natural 
response to anoxia, and that kinases PKC, PTK and MAPKK are required for the 8933-
induced up-regulation of SOD (Duffy and Smith, 2003).  Eventually, one peptide 9236 
was found to decrease infarct volume in a rat model for stroke (Shashoua et al., 2003).  
Future experiments may include the identification and cloning of EPN in other species, 
characterization of the putative EPN receptor, and synthesis of second-generation EPNs.   
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Superoxide Dismutase  
 Superoxide dismutase (SOD) is an anti-oxidative enzyme that catalyzes the 
dismutation of two superoxide anions to hydrogen peroxide and molecular oxygen.  The 
toxic hydrogen peroxide is further rapidly reduced by Catalase or Glutathionine 
Peroxidase (GPX) into water and molecular oxygen, as shown in Figure 3.  SOD is the 
rate limiting enzyme in this pathway (Sun and Chen, 1998; Allen and Tresini, 2000); 
thus, its upregulation is of high therapeutic interest. Superoxide radicals play a 
detrimental role in a variety of neurodegenerative diseases (Venarucci et al., 1999), 
including stroke, and their accumulation ultimately leads to oxidative stress, causing 
cellular damage and death.  The rapid breakdown of superoxide anions is needed to 
minimize overall tissue damage.  Over-expression of SOD in transgenic mice decreases 
infarct volume following ischemia (Sheng et al., 1999a; Sampei et al., 2000) and 
increases resistance to neurotoxin MPTP (Przedborski et al., 1992; Klivenyi et al., 1998).  
Over-expression of SOD in transgenic rabbits provides cardioprotection from myocardial 
infarction (Li et al., 2001).  Levels of c-Jun and c-Fos proteins increased in transgenic 
animals over-expressing SOD, indicating AP-1 may be involved in SOD’s 
neuroprotection against oxidative stress (Huang et al., 2001).  SOD deficiency worsens 
cerebral ischemia in mice (Sheng et al., 1999b).  Therefore, the application of a peptide 
able to increase SOD to levels seen in the transgenic animals might be therapeutic 
following heart attacks or strokes.   
 
 
 20
 
Figure 3.  Biological Function of Superoxide Dismutase. 
 
It is also important to keep in mind that hydrogen peroxide can act as a second 
messenger within the cell (Allen and Tresini, 2000).  Thus some researchers have worried 
that altering its concentration by manipulating SOD will be detrimental to the animal.  
However, in the transgenic models that over-express SOD by as much as 30-fold in all 
tissues, not only are these animal models healthy, but they also resist ischemia 
(Przedborski et al., 1992; Chan et al., 1993; Chan and Kawase, 1998; Sheng et al., 1999 
Li et al, 2001).  Therefore, even if SOD is highly over-expressed, the concentration of 
hydrogen peroxide is regulated closely enough to allow the cell to survive.  
In addition, SOD has been found to have a potential role in deterring the aging 
process.  Cellular oxidative stress increases with age, and is one of the major factors 
contributing to the aging process.  For example, Parkes et al. (1998) performed studies on 
Drosophila melanogaster and found that by over-expressing human SOD-1 in the fly’s 
motor neurons, the fly’s lifespan dramatically increased.  Therefore, the studies 
performed so far on the over-expression of SOD in transgenic models have not shown 
any detrimental effects on these models, but quite the opposite. 
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Mechanism of Action of Full-Length EPN and EPN-NTF Peptides 
Little is currently known about the exact molecular mechanism in vivo by which 
the brain utilizes full-length EPN or the EPN peptides.  Certain EPN mechanistic aspects 
resemble intra-cellular events activated by other NTFs.  AP-1 is a ubiquitous 
transcription factor (Shaulian and Karin, 2002) that is activated by other NTFs, such as 
nerve growth factor (NGF) (Ip et al., 1993; Tong and Perez-Polo, 1996) and brain-
derived neurotrophic factor (BDNF) (Gaiddon et al., 1996).  CMX-8933, a synthetic 
peptide created to mimic a peptide naturally cleaved from EPN, has been shown to 
activate AP-1.  CMX-8933 increased the DNA-binding affinity of two AP-1 nuclear 
factors (a homodimer and a heterodimer) containing c-Jun and c-Fos proteins (Shashoua 
et al., 2001).  It also increased the activity of c-Jun N-terminal kinase (JNK) (an enzyme 
that directly activates AP-1), increased the phosphorylation state of c-Jun protein (a 
component of AP-1), and increased the transactivation of synthetic and natural AP-1 
dependent promoters (Adams et al., 2002).  Because AP-1 has been shown to be a master 
switch that controls long-term memory consolidation (Sanyal et al., 2002), and because 
EPN also functions in long-term memory consolidation (Shashoua and Moore, 1978; 
Schmidt, 1987; Piront and Schmidt, 1988; Schmidt et al., 1995) the activation of AP-1 
may be a key component of EPN’s mechanism of action. 
Based on cumulative data from the Adams and Shashoua labs, we have proposed 
a tentative model for how CMX-8933 activates AP-1 (Figure 4).  Since all known growth 
factors and NTFs act via cell surface receptors, EPN may too (Adams et al., 2002). 
EPN, or its proteolytic cleavage products present in the ECF, may interact with an EPN 
receptor present on the surface of neuronal cells, which initiates a signal transduction 
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cascade involving the MAP kinase pathway and AP-1 as depicted in Figure 4.  Activation 
on protein kinase C (PKC), protein tyrosone kinases (PTKs), and MEK kinase (MEKK) 
(Hasson, 1998) lead to the activation of JNK kinase.  JNK phosphorylates the c-Jun 
component of AP-1, inducing AP-1’s translocation into the nucleus.  Nuclear AP-1 then 
presumably activates AP-1 dependent therapeutic genes, including those for anti-
oxidative enzymes SOD (Parikh, 2003), catalase (CAT), and glutathione peroxidase 
(GPX) (Armitstead, 2001).  Part of the purpose of this thesis is to determine whether 
some of these key MAPK events are necessary for the activation of SOD.  Based on 
information published from other labs about the kind of genes activated by AP-1, this 
information could be used to predict genes other than c-Jun, c-Fos, SOD, CAT, and GPX 
that may be activated by treatment of nerve cells with peptide (Adams et al., 2002).   
 
 
Figure 4.  Working Hypothesis for the Mechanism of Action of Full-length EPN and Peptide 
Mimetic 8933.  The full-length EPN sequence and/or the synthetic mimetic 8933 is thought to 
interact with a receptor on the neuronal cell surface activating the MAP kinase pathway, and JNK 
which phosphorylates the c-Jun component of AP-1 which translocates into the nucleus and 
transactivates genes for the antioxidative enzymes, and others.  This is thought to ultimately lead 
to an increase of antioxidative enzymes within the cell. 
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THESIS PURPOSE 
 
The purpose of this thesis was to test a three-part hypothesis on full-length EPN 
and CMX-8933’s mechanism of action.  It is well established that increases in oxidative 
stress result from neurodegenerative disorders and ischemia.  Recent work in our lab has 
shown that CMX-8933, a synthetic small peptide EPN mimetic, can alleviate ischemic 
damage in a rat model for stroke (Shashoua, unpublished).  Therefore, we hypothesized 
that both full-length EPN, as well as CMX-8933, may help alleviate oxidative stress in 
neuronal cells.  Previous work in our lab showed that CMX-8933 activates the MAPK 
pathway, transcription factor AP-1, and increases cellular levels of SOD protein.  We 
hypothesize that 1) CMX-8933 uses the MAPK pathway to activate SOD.  This pathway 
is also utilized by other common neurotrophic factors.  2) Treatment of rat primary 
cortical cultures with CMX-8933 should up-regulate mRNAs involved in translation, as 
expected for any NTF that functions in neuronal growth.  3)  If CMX-8933 represents the 
receptor binding domain of EPN, full-length EPN, isolated from the extracellular fluid of 
goldfish brains, may have the same effect of alleviating neuronal oxidative stress 
associated with stroke in NB2a cells, by up-regulating superoxide dismutase (SOD), as 
does the naturally occurring synthetic peptide mimetic CMX-8933. 
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MATERIALS AND METHODS 
 
Murine Neuroblastoma Cell Culture Conditions 
 The neuronal cell line grown and maintained for this project was neuroblastoma 
(Neuro-2A).  It was originally derived from mouse brain and neuroblasts.   These cells 
were purchased frozen from American Type Culture Collection (ATCC) (catalog #CCL-
131).  This cell line is an adherent cell line (ATCC, 2003).  Other materials used for cell 
culture included Dulbecco’s Modified Eagle’s Medium (DMEM; with glutamine and 
sodium pyruvate), Trypsin-EDTA solution (0.25% Trypsin; 1 mM EDTA), Fetal Bovine 
Serum (FBS), MEM Non-Essential Amino Acids Solution (100x, 10 mM) and 
Gentamycin (10 mg/ml).  All were purchased from Life Technologies, Inc. 
 
Complete Medium Preparation 
A 500 ml bottle of DMEM culture medium was supplemented with the following 
in order to make it complete medium (final concentrations are in parentheses): Non-
essential amino acids (0.1 mM), Fetal Calf Serum (10%), and gentamicin (5 µg/ml).  The 
contents were filtered aseptically through a pre-sterilized 500 ml filter using a vacuum 
pump, then mixed briefly.  All components used for cell culture were pre-warmed before 
use in a 37°C water bath. 
 
Subculturing 
 
The first step was to thaw the frozen ATCC stock of NB2a cells by rapid (<1 min) 
agitation in a 37°C water bath, and then transfer them to a vented T-25 culture flask 
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diluted with 6 ml of complete medium.  Flasks were incubated at 37°C in a humidified 
atmosphere containing 5% CO2 overnight, then the toxic freezing medium containing 
DMSO was replaced with normal complete medium.  When the cells reached confluency, 
the medium was removed, and the cells were briefly rinsed with a small volume of 
outdated DMEM stock stored at 4°C.  This step was done to remove the FCS proteins.  
The wash was immediately removed, and a small volume (refer to Table 1 for exact 
amounts) of Trypsin-EDTA solution (0.25% Trypsin) was added to just cover the cell 
monolayer.  The flask was then incubated at room temp (or 37° C in the incubator) until 
the cells detached, approximately 2 minutes.  The cells would come off in white sheets 
after the incubation.  An equal amount of fresh complete culture medium was then added 
to the flask so that the FCS in the medium occupies the remaining trypsin. Then the cell 
suspension was transferred to a 15ml plastic tube and centrifuged in a clinical centrifuge 
(25°C, 5 min, 500 x g) to pellet the cells.  The supernatant was then removed, and the cell 
pellet was re-suspended in fresh culture medium, and the cells were dispensed into new 
sterile flasks. 
Table 1: Overview of Some Specific Culture Amounts Used 
Flask Type Amt. Used For 
Trypsinizing 
Amt. Used For Washes Normal Total ml in 
Flask During Culture 
T-25 2 ml 3 ml 6 ml 
T-75 5 ml 10 ml 40 ml 
T-150 7 ml 20 ml 60 ml 
 
 The normal split ratio specified by the ATCC was 1:3 to 1:6, and this is what was 
used for the most part. Feeding the flasks was normally done twice or three times a week.  
When aliquots were to be frozen, the freezing medium was normal complete culture 
medium plus 5% filtered DMSO.  A total of 2 ml of cells from two flasks were frozen at  
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-80°C, then moved to liquid nitrogen.  One T-25 flask was maintained between 
experiments. 
 
Drug Treatment  
For whole cell lysate experiments, confluent T-25 flasks were used, and treated 
with various amounts of ECF or the dialyzed ECF. 
For the inhibition experiments, Calphostin-C (250 nM), Genistein (15 µM), PD-
98059 (10 µM) or PDTC (500 µM) were added to the medium at 5X IC50 concentrations 
5 minutes prior to the addition of CMX-8933. 
 
RT-PCR Experiments with Translation Factors  
At Ceremedix Inc., CMX-8933 was synthesized by the Merrifield process 
(Shashoua et al., 2001) and purified by HPLC to give a 99.5% pure white solid.  The 
structure was confirmed by amino acid analysis and mass spectroscopy.  Mass 
spectroscopy was also used to verify the absence of trifluroacetic acid.  The peptide was 
converted to its acetate salt, and lyophilized to yield a product that was stable for at least 
three months at 4°C.  Peptide was dissolved in cell culture medium just prior to use.  Rat 
primary cortical culture flasks obtained from Ceremedix Inc. were treated with 10 ng/ml 
of peptide CMX-8933 for 5 hours, followed by RNA isolation.   
 
Isolation of Total Cellular RNA 
 Total cellular RNA was isolated from the rat primary cortical cultures discussed 
above using the Clontech Atlas Pure Total RNA Labeling System (# K1038-1). 
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Cell Collection 
 
The first step in the RNA isolation process was to use a plastic cell scraper to 
dislodge the cells from the bottom of the flask.  The cell suspension was then poured into 
a 15ml or 50ml plastic tube, and centrifuged in a clinical centrifuge for 5 minutes at about 
2,000 rpm (500 x g, medium setting) to pellet the cells.  The supernatant was then 
discarded, leaving a small volume of medium for cell transfer.  The pellet was 
resuspended in a small volume of the supernatant, and transferred into 2 ml sterile 
eppendorf tubes.  Typically 2 ml eppendorf tubes were used for experiments using cell 
counts ranging from 106 to 107 total cells.  The tubes were then microfuged for 5 minutes 
at about 2,000 rpm at 4ºC to pellet the cells.  The supernatant was then thoroughly 
removed, sometimes spinning the tubes twice to remove extra supernatant. 
 
Cell Lysis 
For a total cell count of 107 cells split between 2 epp tubes, 0.25 ml of denaturing 
solution (1 M NaOH, 10 mM EDTA) was added to each cell pellet.  The cells were re-
suspended completely by pipetting up and down vigorously, and vortexing.  The solution 
was then incubated on ice for 5-10 min, and then re-vortexed.  The tubes were 
microfuged at 12,000 rpm for 5 minutes at 4ºC in order to pellet cellular debris.  
Following centrifugation, the supernatant (a volume of approximately 0.5 ml) was 
removed and transferred to new sterile 2 ml eppendorf tubes. 
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Phenol Extraction 
  A volume of 0.5 ml of TE saturated phenol (an equal volume) was added to each 
tube.  Tubes were securely closed and vortexed vigorously for one minute, then placed on 
ice for five minutes.  0.15 ml of chloroform was then added to each tube to make a total 
volume of 1.15 ml.  The tubes were vortexed vigorously for one to two minutes, assuring 
that the tubes did not leak, and then placed on ice for five more minutes.  After 
incubation on ice, the tubes were centrifuged at 12,000 rpm for ten minutes at 4ºC to 
separate aqueous and phenolic phases.  Avoiding the white interphase and lower organic 
phase of the sample, the upper aqueous phase containing RNA (approximately 0.5 ml) 
was then transferred to a new sterile eppendorf tube.  For samples expected to contain 
low amounts of RNA 1 µl of 20 mg/ml, glycogen was added to the sample to act as a 
carrier.     
 Next, a second round of saturated phenol and chloroform extraction was 
performed on the aqueous phase.  Note that this second extraction was skipped for 
samples containing low amounts of RNA to which glycogen was added.  First, 0.4 ml of 
saturated phenol was added per aqueous phase from one tube; the sample was mixed for 
one minute, and incubated on ice for 5 min.  Then 0.15 ml of chloroform was added, the 
sample was vortexed for 1-2 min, incubated on ice for 5 min, and then centrifuged at 
12,000 rpm for 10 min at 4ºC.  Once again, the upper aqueous phase was then transferred 
to new eppendorf tubes.        
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Isopropanol Precipitation 
A volume of 0.5 ml of isopropanol was slowly added to the 0.5 ml of supernatant 
in each tube and mixed.  The tubes were incubated on ice for 10 min, and then 
centrifuged at 12,000 rpm for 15 min at 4ºC to the pellet the RNA.  Once centrifuged, the 
supernatant was carefully removed and discarded, without disrupting the RNA pellet.   
 
Pellet Wash 
Then 0.25 ml of 80% ethanol was added to the pellet, and the tubes were once 
again centrifuged at 12,000 rpm for 5 min at 4ºC.  Being very cautious to not disturb the 
loose RNA pellet now present, the supernatant was removed and discarded from each 
tube.  The tubes were left on the bench allowing the pellets to air dry, or the vacuum 
drying apparatus was used to expedite the drying process.   
 
Pellet Dissolution 
Once the RNA pellet had completely dried, 40 µl of RNase-free dH20 water was 
added, producing an RNA concentration of 1-2 µg/µl.  The tube was then heated at 50ºC 
for 5 minutes, occasionally flipping the tube to dissolve the RNA.  It was then briefly 
microfuged.  For OD 260 analysis, 1 µl of the final solution was aliquoted and added to 1 
ml dH2O prior to UV spectrophotometry.  The rest of the RNA was aliquoted into several 
epp tubes (about 10 µl per tube) to avoid repeated freeze/thaw.  The samples were labeled 
and stored at -80ºC for later use. 
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Assessing the Integrity of Total RNA 
 Before the RT-PCR was performed, the integrity of the total cellular RNA 
samples was assessed.  This was done by preparing and running a denaturing agarose gel 
as described in the Clontech Atlas™ Pure Total RNA manual.  Before the gel was made, 
a mini-gel box, gel tray and combs were washed with deionized water.  For the 
preparation of the gel, a 250 ml beaker with a magnetic stir bar was obtained, and 1 gram 
of agarose was weighed into the beaker and mixed with 82.5 ml of deionized water.  The 
solution was microwaved for 2 min, then placed on a magnetic stir-plate under the hood 
and stirred slowly for 2 min to cool.  While the solution was stirring, 10 ml of 10X 
MOPS buffer (0.4 M MOPS pH 7.0 , 0.1 M NaOAc pH 7.0, and 10 mM EDTA pH 7.0) 
and 7.5 ml of formaldehyde were added, and stirring was continued for 1 min.  The 
solution was taken from the hood and poured into the gel tray.  The gel was left to 
solidify at room temperature for one hour.  The gel comb was then removed and the gel 
was submerged in the gel box with 1X MOPS buffer. 
The RNA loading solution was made immediately before the gel was to be run.  
The solution was made to accommodate 6-10 samples and consisted of: 45 µl of 
formaldehyde, 45 µl deionized formamide, 10 µl 10X MOPS buffer, 3.5 µl EtBr (10 
mg/ml), 1.5 µl 0.1 M EDTA (pH 7.5), and 8 µl bromophenol blue dye (in 50% glycerol to 
make a total of 113 µl).  A volume of 15 µl of RNA loading solution was added to 2 µg of 
total RNA (usually about 2 µl) and mixed well.  The solution was heated in the thermal 
cycler at 70ºC for 15 min, and then cooled on ice for 1 min.  The sample solutions were 
then loaded into the wells of the gel, and electrophoresed at 60-70V until the blue dye 
reached the midpoint of the gel.  The RNA was visualized on a UV transilluminator.  
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Strong discrete 18S and 28S rRNA bands indicated intact RNA for that sample.  The 28S 
band should predomintae at a ratio of 1.5-2.5 :1.0. 
 
Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
To test whether the primary rat cortical RNA samples expressed genes of 
particular interest, RT-PCR was performed using Ambion’s RETROscript, First Strand 
Synthesis Kit for RT-PCR Protocol (Catalog #1710).  The procedure followed the 
RETROscript Protocol (Two-Step RT-PCR) and all the reagents came with the kit.  In 
addition, some Ready-To-Go RT-PCR beads in 0.5ml tubes were used from Amersham 
Pharmacia Biotech (www.apbiotech.com).  These tubes already contained all of the 
reagents described below but needed the addition of the primers, RNA and dH2O.  Then 
they followed the same procedure as the above two-step RT-PCR.  All primers used were 
purchased through Fisher Sigma Genosys and were designed for the rat sequence using 
the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/). 
 
Reverse Transcription of the RNA 
 
 The following items were added to 0.5 µl eppendorf tubes: a total of 2 µg RNA,   
2 µl of the anti-sense oligo (dT) (50 µM) and enough nuclease-free dH2O to total 12 µl.  
This was mixed, spun briefly in a microcentrifuge at room temperature, and heated for 3 
min at 70-85°C in the thermal cycler.  The tubes were then removed, spun again briefly 
and placed on ice.  The remaining RT components were then added: 2 µl of 10x RT 
buffer (500 mM Tris pH 8.3, 750 mM KCl, 30 mM MgCl2, 50 mM DTT), 4 µl dNTP 
mix, 1 µl RNase inhibitor, and 1 µl MMLV reverse transcriptase to make a total volume 
of 20 µl.  The reaction was mixed and spun again, and then incubated at 42-44°C for one 
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hour in the thermal cycler.  Upon completion of the reverse transcription, the reactions 
were then incubated at 92°C for 10 min to inactivate the reverse transcriptase.  After this 
point, the samples could be stored at -20°C, or the procedure could continue to PCR.   
 
PCR  
The following components were added to 0.5 ml eppendorf tubes: 5 µl RT 
reaction (containing the antisense primer and cDNA), 5 µl 10x PCR buffer, 2.5 µl dNTP 
mix, 37.5 µl nuclease-free dH2O, 2.5 µl PCR sense primers (50 µM stock) and 0.4 µl 
thermostable Taq DNA polymerase (5 units/µl).  The samples were mixed, spun briefly 
and then placed in the thermal cycler for the following program: 94-95°C for 2-4 min 
initial denaturation, 30 cycles of 94°C for 20-30 seconds, annealing for 20-30 seconds 
(usually at 55°C unless otherwise stated), 72°C for 40 seconds to 1 min, and finally a 
polishing step at 72°C for 5 min once.  The samples were then stored at 4°C overnight in 
the thermal cycler, or used immediately. 
 
Analysis of RT-PCR Reactions 
To analyze the RT-PCR reactions, aliquots of the reaction mixes were loaded onto 
a non-denaturing agarose gel in the presence of ethidium bromide, and then visualized 
under UV light.  A total of 2 µl of the high-resolution gel loading solution included in the 
Ambion kit was mixed with 10 µl of the RT-PCR mix, and 10 µl of this 12 µl mixture 
was loaded into the wells of the gel.  Since the TBE-based loading dye that came with the 
kit was used, a 1X TBE (Tris-borate-EDTA) buffer was used to make the gel solution and 
electrode buffer.  A 2.5% agarose gel containing about 0.5 µg/ml of ethidium bromide 
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was typically used.  The remaining RT-PCR products and PCR reaction mixes were 
stored at -20°C. 
 
Western Blots Analysis 
 Western blots were used to analyze the levels of SOD protein in NB2a neuronal 
cell lysates, and the levels of full-length EPN in goldfish ECF.   
 
Whole Cell Extracts 
 Whole cell extracts were prepared from in vitro cultured NB2a cells in T-25 
flasks, in order to obtain protein for immunoblots.   
 
Cell Harvesting 
The flasks were collected and the media was poured off and 10 ml of ice-cold 
PBS-EDTA (1X PBS, 20 mM EDTA) was added to each flask.  Using a plastic scraper, 
the cells were scraped into the PBS and then removed with a pipette.  The suspension was 
placed in 15ml conical tubes and pelleted at 500 x g for 5 minutes.  The PBS was then 
discarded, and the cell pellet was washed once with ice cold PBS-EDTA, and centrifuged 
again as previously described.  Once again the wash was discarded, then the tube was 
briefly inverted onto a towel to get rid of as much of the PBS as possible.  Then the tube 
was placed on ice.   
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Cell Lysis 
 Once all the PBS wash was removed, 200 µl (for a small cell pellet from a T-25 
flask) of Complete Lysis Buffer (20 mM HEPES pH 7.9, 10 mM KCl, 300 mM NaCl, 1 
mM MgCl2, 0.1% Triton X-100, 20% Glycerol, and freshly added 0.5 mM DTT and 0.5 
mM PMSF) was added to each pellet from one T-25 cultured flask.  Using a blue-tip, the 
cell pellet was re-suspended in the buffer and then transferred to 1.5 ml epp tubes on ice.  
The suspension was incubated on ice for at least 10 min to thoroughly lyse the cells.   
 
Lysate Clarification 
 The pellet was then microfuged at 4°C for 5 min to pellet cell debris.  The 
supernatant was put into 0.5 ml epp tubes (about 40 µl per tube) and 1 µl of the 
supertatant was put into 0.5 ml of dH2O for protein determination (1:500) using 
Coomassie Reagent (Pierce).  The tubes were stored at –80°C. 
 
Protein Determination 
 BSA protein standards were prepared (1.25, 2.50, 5.00, 10.00, 20.00, 40.00 
µg/ml) and 0.5 ml of each were added to 1.5 ml epp tubes.  A blank was prepared with 
0.5 ml of dH2O.  Next, 10 µl or 5 µl of the sample plus 0.5 ml of dH2O were put into 1.5 
ml epp tubes.  All tubes were then put into a water bath for 10 min to ensure that all were 
at the same temperature.  The tubes were then microfuged, and 0.5 ml of Coomassie 
Reagent were added to all tubes.  The tubes were then vortexed to mix.  The 
spectrophotometer was set at OD 595 nm, and zeroed on the dH2O blank.  All samples 
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were read, then a BSA standard curve was created and used to determine protein 
concentration in the whole cell lysate. 
 
Protein Gels and Immunoblots 
 Protein gels were used to test goldfish brain extracellular fluid for the presence of 
EPN (refer to Appendix 1-6 for exact whole cell lysate information used to assess ECF 
protein content used for the western blots). The samples were run with the kaleidoscope 
marker.  Also, Western blots were performed to measure SOD levels in whole cell lysates 
prepared from in vitro cultured mouse neuroblastoma (NB2a) cells. 
 
Gel Polymerization 
A BRL V-16 glass plate apparatus was assembled using two non-siliconized glass 
plates (the front plate being 6 x 8 inches, the back plate 6 x 6 inches), and 0.8 mm thick 
spacers, held secure with clamps around the edges of the plates.  The first gel, a lower 
resolving gel, was poured first as the base layer.  It was composed of 7.6 ml of distilled 
H2O, 6.7 ml of 30% acrylamide (2.7% crosslinking), 5.1 ml of resolving gel buffer (1.5 
M), 200 µl of 10% SDS, 400 µl of 5% ammonium persulfate, and 10 µl of TEMED 
(added just prior to pouring the gel as a catalyst which initiates gel polymerization).  The 
solution was poured between the two plates to about 1.5 cm from the top.  A thin layer of 
dH2O was put on the top in order to level off the top of the gel, and to make sure the 
lower gel was in a straight line.  The gel was then allowed to polymerize for 20 minutes. 
 After the lower resolving gel had fully polymerized, the water was poured off and 
the upper stacking gel was poured on.  The upper stacking gel was composed of 5.52 ml 
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of distilled H2O, 1.67 ml of 30% acrylamide (2.7% crosslinking), 2.5 ml of stacking gel 
buffer (0.5 M), 100 µl of 10% SDS, 200 µl of 5% ammonium persulfate, and 10 µl of 
TEMED (added just prior to pouring the gel as a catalyst which initiates gel 
polymerization).  The upper stacking gel was poured on top of the lower resolving gel 
until it reached the top of the smaller back glass plate.  A 20-stall comb was then 
carefully placed between the two plates, with about 0.5 cm into the upper stacking gel, 
making sure no air bubbles were in the gel).  The gel was then allowed to polymerize for 
another 20 minutes.  If the gel was left overnight, the top of the plates was covered with 
plastic wrap so that the gel would not dry out. 
 
Gel Electrophoresis 
 When the gel was completely polymerized, the clamps and the lower spacers were 
removed.  After making sure that the black gaskets on the side spacers were pushed 
down, with no space between them and the top of the smaller plate, the plates were then 
mounted into the V-16 vertical electrophoresis unit, secured in place by clamps on both 
sides.  Protein electrode buffer (25 mM Trizma Base, 0.192 M Glycine, 0.1% SDS) was 
then poured in the upper reservoir to check for leaks, if no leaks were present, then it was 
also poured in the lower reservoir until level with the electrodes.  The comb was then 
removed, the wells were flushed out, and the gel was pre-run for one hour at 150 volts.  
After the pre-run, the samples were prepared for electrophoresis by inserting them in a 
boiling water bath for two minutes, and then microfuging briefly.  Samples were then 
loaded into each well (3 µl loads were used per lane corresponding to 5 µg of protein 
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unless otherwise noted), and electrophoresed for about 3 hours at 150 volts so that the 
dye traversed down ¾ of the gel.     
    
Protein Staining of Gel 
 Visualization of ECF proteins was achieved by Coomassie blue staining.  When 
the gel was finished running, it was removed from the electrophoresis apparatus and the 
area containing the samples was trimmed.  This area was then placed in a Tupperware 
container with 100 ml of staining solution (0.25% Coomassie Blue, 40% Methanol, 9% 
Acetic acid) and stained until it turned blue.  Then, the staining solution was discarded 
and 100 ml of de-staining solution (5% Methanol, 7% Acetic Acid) was added to the 
Tupperware container and left for between 1-2 days.  The gel was photographed using a 
white light transilluminator.   
 
Western Protocol - Gel Transfer 
 After the 3 hours of electrophoresis, the side spacers were removed, and one of 
the glass plates was carefully taken off.  A notch was made in the original right corner of 
the gel, as an orientation aid, so the bands could be viewed in the correct order.  The gel 
was trimmed to contain only the sample area, and then a nitrocellulose membrane was cut 
to cover the gel (notched on the same side to match the notch in the gel).  It was then 
surrounded on both sides by two pieces of 3 MM paper, all presoaked in transfer buffer 
(48 mM Trizma base, 39 mM Glycine, 0.037% SDS, and 20% Methanol) from the 
electroblotter.  The gel/membrane sandwich was then placed in the plastic electroblot 
holder (with sponges on either side), fastened shut, and placed in the electroblot unit, 
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submerged in chilled transfer buffer.  The nitrocellulose membrane side must face the 
positive anode to ensure proper protein transfer from the gel to the membrane.  The 
membrane was then transblotted in the refrigerator at 4°C, on a slow speed stir, for 2 
hours at 50 volts. 
 
Membrane Blocking/Antibody Incubations 
 Once the membrane had been transblotted, it was removed from the unit and 
placed in a Tupperware hybridization tray for blocking.  The side that originally was in 
contact with the gel was marked with a felt pen, and remained face up at all times.  The 
membrane was blocked with 50 ml of freshly made chilled blocker (1X PBS, 1% Casein 
powder, and 0.2% Tween-20) for one hour, mixing at low speed on the red rocker shaker.  
After the block, if the sample was to be tested for SOD, the blocker was replaced with 
fresh blocker, and 50 µl of the primary antibody (rabbit anti-SOD, Rockland [Penn], 
catalog #100-4191, main stock: 90 mg/ml) was added to the liquid, not directly onto the 
membrane.  If EPN protein was being detected, 500 µl of 1:50 antibody Sheila (rabbit 
anti-goldfish C-terminal end of EPN) was added to the 50 ml blocker.  The membrane 
was then left to mix again, as previously described for two hours.  After the incubation 
with the primary antibody, the solution was removed, and the membrane was washed 
twice in PBS-Tween, 5 minutes each time, at a vigorous rate on a gyratory shaker (the 
volume of liquid was just enough to cover the entire membrane).  Next, the membrane 
was incubated with 50 ml of fresh blocker supplemented with 50 µl of the secondary 
antibody (goat anti-rabbit-HRP, Pierce, catalog #31460, final concentration: 0.4 µl/ml) 
for two hours on the red rocker shaker.  After the two-hour incubation with the secondary 
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antibody, the used solution was removed, and the membrane was washed four times (3 
times in PBS-Tween, once in 1X PBS, each for 5 minutes on the gyratory shaker at 
vigorous speed) before x-ray development. 
 
Chemiluminescent Detection/X-ray Film Development 
 After the last washes, the membrane was moved from the hybridization tray to a 
piece of foil on the bench top, protein side up.  In a 15 ml conical tube, the detection 
solution (5 ml Luminol/Enhancer Solution plus 5 ml Stable Peroxide Solution) was 
mixed.  The freshly prepared solution was then poured on the membrane, and spread 
evenly with a glass pipette and allowed to incubate for 5 minutes.  After 5 minutes, the 
membrane was picked up using tweezers, and the corner was dabbed with a Kimwipe to 
remove excess detection solution.  The membrane was placed between two sheets of clear 
plastic Photogene Development Folders (Gibco BRL #18195-016), and any air bubbles 
were removed by rubbing a Kimwipe over the plastic surface.  The folder was then 
placed in a film cassette without a screen for transportation to the darkroom for 
development.   
 Before developing, the development tank was filled with water at a constant 25°C 
maintained throughout development.  Kodax X-Omat AR film was exposed to the 
membrane for ~1-10 seconds for SOD, or for 20 sec for EPN).  The film was then placed 
in the GBX developer, agitating initially to remove air bubbles, and left for 5 minutes.  It 
was then removed, dipped briefly in the water to remove the developer, and submerged 
into the fixative solution for three minutes, with intermittent agitation over the entire 3 
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minutes.  Finally, the film was placed in the water bath for 5 minutes to remove excess 
fixative, and hung to air dry.  Bands were quantitated using Scionimage Software (NIH). 
 
Microdialysis 
 Microdialysis was performed to remove low molecular weight components from 
the ECF, such as any naturally occurring proteolytic cleavage products of full-length 
EPN, retaining the higher molecular weight components.  The Pierce Microdializer 
System 500 (Catalog # 66350) with a 5 x 500 µl sample capacity was used, along with 
Pierce framed dialysis Membranes with a MW cutoff of 8,000 (Catalog # 66310).   
First, the framed membrane was put into place, then a syringe was used to deliver 
1X PBS Buffer into the bottom of the dializer.  A volume of 200 µl of ECF was added to 
each sample well.  The apparatus was then covered and placed in the 4°C refrigerator, 
and left overnight with a spinning magnet on low speed.  After the overnight incubation, 
the buffer was removed and fresh ice-cold 1X PBS buffer was replaced.  The unit was 
incubated for another 2 hours, and then the dialyzed ECF in the well (approximately 200 
µl) was put into 1.5ml epp tubes and stored in the 4°C refrigerator.    
 
 
 
 
 
 
 
 41
RESULTS 
 
 The goal of this thesis project was to test three hypotheses involved in 
investigating the mechanism of action of both full-length EPN and CMX-8933.  The first 
part of the thesis investigated which signal transduction pathway is responsible for CMX-
8933’s upregulation of SOD found previously in our lab (Parikh, 2003).  Because our lab 
previously showed that CMX-8933 activates the MAPK pathway (Hasson, 1998; Adams 
et al., 2003) we hypothesized that CMX-8933 may use this pathway to upregulate SOD. 
 
CMX-8933 Uses the MAPK Pathway to Upregulate SOD in Rat Primary Cortical 
Cultured Cells 
 Inhibition experiments were performed to test three known components of the 
MAPK pathway, as well as one member of an unrelated pathway from the NF-κB family.   
Calphostin-C (CAL) inhibits members of the protein kinase C family (PKC) (for a 
review, see: Tamaoki and Nakano, 1990).  Genistein (GEN) inhibits members of the 
protein tyrosine kinase family (PTK) (Akiyama et al., 1987; Platanias and Colamonici, 
1992).  PD98059 (PD) inhibits MEK members of the MAP kinase kinase (MAPKK) 
family (Dudley et al., 1995).  All these kinases have previously been shown to be critical 
components the MAPK pathway (Akiyama et al., 1987; Plantanias and Colamonici, 
1992; Dudley et al., 1995).  Pyrrolidine dithiocarbonate (PDTC) inhibits anti-oxidative 
members of the NF-κB family, an unrelated pathway (Schreck et al., 1992; Tsai et al., 
1996). 
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Six independent SOD Western experiments were performed (Figure 5) using 
whole cell lysates prepared from in vitro cultured rat primary cortical cells treated for 5 
minutes with an inhibitor before a 5 hour treatment with CMX-8933.  SOD protein levels 
were compared to a control with no treatment of peptide (lane “ctrl”) and to cultures 
treated with 8933 but no inhibitor (lane “0”).  The 10 ng/ml of CMX-8933 treated culture 
without any inhibitor (lane “0”) showed a dark SOD band at the expected size of SOD 
protein (34 kDa), as expected (Parikh, 2003).  A strong SOD signal was also seen in the 
sample treated with inhibitor PDTC, indicating NK-kB plays no role in CMX-8933’s 
activation of SOD.  However, levels of SOD showed no increase above untreated 
cuoltures when inhibitors CAL, GEN or PD were pre-incubated with the peptide treated 
flasks.  The bands were quantified using Scionimage Software.  The histobars shown 
below each panel indicate the fold increase relative to untreated sample.  The results of 5 
additional independent experiments (panels B and C) show identical data to trial-1. 
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Figure 5.  Inhibitors CAL, GEN, and PD Inhibit CMX-8933-Induced Increases in SOD 
Levels in Rat Primary Cortical Cells.   Rat primary cortical cultures were pre-incubated with an 
inhibitor at its IC50 concentration (see Methods) for 5 min, then 10 ng/ml of CMX-8933 was added 
for a period of 5 hours.  Panel A represents Trial-1, while Panels B and C represent five additional 
trials.  Arrows to the right denote the positions of the 34 kDa SOD-1.  Arrows to the left denote 
positions of the biotinylated marker. 
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The means of Trials 1 through 6 for the in vitro inhibition experiment are 
illustrated in Figure 6.  Treatment of the rat primary cells with 10 ng/ml CMX-8933 for 5 
hr increased SOD an average 14-fold relative to untreated, as expected (Parikh, 2003).  
No significant difference (p = 0.901) occurred between lanes “0” and “PDTC”, indicating 
no involvement of NF-kB.  In the presence of inhibitors CAL, GEN and PD, the cellular 
titers of SOD showed no observable difference from the control sample.  The data 
implicate the involvement of components of the MAPK pathway in CMX-8933’s 
upregulation of SOD. 
 
Figure 6:  Statistical Analysis of Six in Vitro Inhibition Experiments.  Error bars denote 
standard deviation calculated in Excel.  P values were calculated using a student’s two- 
tailed T-test in Excel.  * denotes histobars 2 and 3, compared for p value 0.901.  ~ denotes 
histobars 2 and 4, compared for p value 0.0001. 
 
CMX-8933 Upregulates mRNAs Related to Translation 
 The second part of this thesis was designed to determine whether treatment of rat 
primary cortical cultures with CMX-8933 increases the cellular titers of mRNAs related 
to translation.  Previous observations indicated treatment of rat primary cortical cultures 
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or mouse NB2a cultures with CMX-8933 induced neurite sprouting (Shashoua, 
unpublished), and that EPN plays a role in optic nerve elongation (Schmidt and 
Shashoua, 1988), so we hypothesized that EPN or its derived peptides may stimulate the 
transcription of mRNAs related to growth.  We decided to test mRNAs for translation 
factors and ribosomal proteins based on previous observations in our lab with 
hybridization arrays (Parikh, 2003). 
 
Isolation of Total Cellular RNA from Rat Primary Cortical Cultures Cells 
 Cultured rat primary cortical cells at confluence were treated with 10 ng/ml of 
CMX-8933 for a period of 5 hours prior to total cellular RNA isolation.  Table 2 
summarizes some of the neuronal cell samples tested in this thesis, along with their 
corresponding RNA yields after the isolation procedure. 
 
Table 2.  Rat Primary Cortical Cell Sample Size and Corresponding RNA Yields 
Date Sample Flasks RNA Yield µg Conc. µg/µl 
12/12/02 Control 1 2, T-75 35.3 0.84 
12/12/02 Drug 2 2, T-75 38.6 0.42 
12/12/02 Control 3 2, T-75 17.6 0.92 
12/12/02 Drug 4 2, T-75 17.6 0.42 
 
In order to verify that the isolated RNA was intact, denaturing formaldehyde 
agarose gel electrophoresis was performed.  Discrete 28S and 18S ribosomal RNA bands 
were used as indicators of intact RNA.  Figure 7 shows the RNA integrity gel for the 
above samples in Table 2.  The 28S and 18S ribosomal RNA bands at 4.5 kb and 1.9 kb 
can be clearly seen in each sample indicating that the RNA was intact. 
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Figure 7: RNA Integrity Gel by Denaturing Formaldehyde Agarose Gel Electrophoresis. 
Analysis of total cellular RNA isolated from rat primary cortical cells. 
  
Previous multiple gene profiling, using Clontech’s Atlas Nylon Rat cDNA Arrays, 
indicated mRNAs for several ribosomal proteins increased in rat primary cortical cells 
treated with 8933 (Table 3). 
 
Table 3.  Hybridization Array Summary Table for Ribosomal Proteins and EF-2 (Parikh, 
2003).   Bold text indicates candidate primers chosen for investigation in this thesis.  +++ on the 
array signal is strong, ++ is moderate, and + is a weak signal. 
   
ARRAY 
COORDINATE 
GENBANK 
ACCESSION 
GENE/PROTEIN CLASSIFICATION ARRAY SIGNAL 
CTRL           8933 
C11e M18547 Ribosomal Protein 
S12 
Ribosomal Protein ++ +++ 
C11g X62184 Ribosomal Protein L11 Ribosomal Protein + ++ 
C11h X78327 Ribosomal Protein L13 Ribosomal Protein + ++ 
C11j X53504 Ribosomal Protein L12 Ribosomal Protein + ++ 
C11k X51707 Ribosomal Protein S19 Ribosomal Protein + ++ 
C11L M27905 Ribosomal Protein L21 Ribosomal Protein + ++ 
C11m J02650 Ribosomal Protein 
L19 
Ribosomal Protein ++ +++ 
C12d K03502 Elongation Factor-2 Translation Factor ++ +++ 
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RT-PCR:  CMX-8933 Increases the Titer of mRNAs Involved in Translation 
 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) was performed to 
verify the preliminary array results.  Translation candidates ribosomal protein R-S12, 
ribosomal protein R-L19 and elongation factor-2 were chosen for investigation by RT-
PCR because of their strong signals on the array.  Figure 8 shows the RT-PCR result for 
ribosomal protein R-S12 performed in triplicate on independent samples.  As predicted, 
the levels of the housekeeper Polyubiquitin (amplicon size 231 bp) were equal between 
treated and untreated samples, while levels of R-S12 mRNA (amplicon size 286 bp) 
increased in all 3 drug-treated samples. 
 
 
 
 
 
Figure 8.  CMX-8933 Elevates R-S12 mRNA Levels in Rat Primary Cortical Cells.  
Polyubiquitin (amplicon size 231 bp) was used as a housekeeper, shown in the bottom panel in 
each test.  The results of 3 independent trials indicated that the R-S12 bands (amplicon size 286 
bp) were stronger in all 3 samples treated with 10 ng/ml of CMX-8933 for 5 hours.  This data 
correlates with the preliminary results obtained from the hybridization array. 
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 The means +/- standard deviation for the 3 trials shown in Figure 8 are shown in 
Figure 9.  The histobars show the mean fold increase quantitated using Scion image in a 
triplicate determination. Error bars denote standard deviations within triplicate set.  This 
figure shows an average 12 fold increase in R-S12 mRNA levels for the 8933 treated 
samples compared to the control.  A statistical analysis was performed using the two-
tailed student T-test in Microsoft Excel.  It indicated that R-S12 up-regulation was 
significant (p = 0.02). 
 
Figure 9.  Quantitation Data for R-S12 RT-PCR.  Histobars indicate means for 3 independent 
trials.  Error bars denote standard deviations in the triplicate set.  Asterisks denote the two 
histobars compared for the p value. 
 
 The second candidate tested by RT-PCR was ribosomal protein R-L19.  Figure 10 
illustrates the RT-PCR results performed in triplicate. As predicted, the levels of the 
housekeeper Polyubiquitin (amplicon size 231 bp) were equal between treated and 
untreated samples, but R-L19 mRNA (amplicon size 257 bp) increased in all 3 drug 
treated samples.  The mean 9-fold upregulation was significant (p = 0.048) (figure 11). 
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Figure 10.  CMX-8933 Elevates R-L19 mRNA Levels in Rat Primary Cortical Cells.  
Polyubiquitin (amplicon size 231 bp) was used as a housekeeper, shown in the bottom panel in 
each test.  The results of 3 independent trials indicated that the R-L19 bands (amplicon size 257 
bp) were stronger in samples treated with 10 ng/ml of CMX-8933 for 5 hours.  This data correlates 
with the results obtained from the hybridization array. 
 
 
Figure 11.  Quantitation Data for R-L19 RT-PCR.  Histobars indicate means for 3 independent trials.  
Error bars denote standard deviations in triplicate set.  Asterisks denote the two histobars compared for the 
p value calculated by the two-tailed T-test. 
 
 The third candidate tested was elongation factor 2 (EF-2).  Figure 12 illustrates 
the EF-2 RT-PCR results performed in triplicate. As predicted, the levels of the 
housekeeper Polyubiquitin (amplicon size 231 bp) were equal between treated and 
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untreated samples, but EF-2 mRNA (amplicon size 227 bp) increased in all 3 drug-treated 
samples.  The mean 11-fold upregulation was significant (p = 0.045) (figure 13). 
 
Figure 12.  CMX-8933 Elevates EF-2 mRNA Levels in Rat Primary Cortical Cells.  
Polyubiquitin (amplicon size 231 bp) was used as a housekeeper, shown in the bottom panel in 
each test.  The results of 3 independent trials indicated that the EF-2 bands (amplicon size 227 bp) 
were stronger in samples treated with 10 ng/ml of CMX-8933 for 5 hours.  This data correlates 
with the results obtained from the hybridization array. 
 
 
Figure 13.  Quantitation Data for EF-2 RT-PCR.  Histobars indicate means for 3 independent 
trials.  Error bars denote standard deviations in the triplicate set.  Asterisks denote the two 
histobars compared for the p value calculated by the two-tailed T-test. 
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Full-Length Ependymin Increases SOD Levels in Mouse NB2a Cells 
 The third part of this thesis investigated the stimulatory effects of full-length EPN 
versus its cleavage product 8933.  Previous research showed that true neurotrophic 
factors BDNF and NGF can upregulate SOD in neuronal cells.  CMX-8933 can also 
upregulate SOD in neuronal cells (Parikh, 2003).  We hypothesized that if 8933 
represents the receptor-binding domain of EPN, that full-length EPN may show the same 
stimulating effects as 8933.  Therefore full-length EPN may also upregulate SOD in 
neuronal cells.   
The first step in testing thesis hypothesis 3 was to isolate goldfish brain 
extracellular fluid, and to verify that it does indeed contain full-length ependymin (Figure 
14).  Goldfish ECF is the normal source for isolating EPN (for a review, see Shashoua, 
1991).   
 
Figure 14: Coomassie Protein Gel Analysis of Goldfish Extracelluar Fluid.  Arrows to the 
right denote the 37 and 31 kDa EPN bands.  Arrows to the left denote the positions of the 
biotinylated markers. 
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Figure 14 shows the presence of numerous proteins in the extracellular fluid, and  
the most prominent/abundant of these proteins are at 31 and 37 kDa.  These results are 
exactly as expected since the two forms of EPN have previously been shown to 
predominate in the extracellular fluid of goldfish at exactly these sizes (Shashoua, 1991). 
 However, to make certain that these bands are indeed full-length ependymin, the 
extracellular fluid sample was tested in an EPN immunoblot using rabbit anti-EPN 
antibody induced in rabbits with a synthetic peptide representing the C-terminal end of 
goldfish EPN (Shashoua and Moore, 1978) (termed antibody Sheila, graciously donated 
by Dr. Dan Gibson, WPI).  Figure 15 illustrates the results of the EPN western blot 
analysis.  
 
Figure 15: Analysis of EPN Protein in Goldfish Extracellular Fluid by EPN Immunoblot.  
Lane 1 is the kaleidoscope marker.  Lanes 2-4 show increasing amounts of goldfish extracelluar 
protein in each lane.  Arrows on the right denote the 37 and 31 kDa expected size bands for full-
length ependymin.  Arrows to the left denote the positions of the biotinylated markers. 
 
  
Together, Figures 14 and 15 show that full-length EPN resides in our ECF preparation.   
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 Next, NB2a cells were treated with 200 µl (12 µg/ml ECF protein) of the goldfish 
ECF for 5 hours to see if SOD levels increased (Figure 16).   The two ECF-treated 
samples showed 3-4 fold increases in SOD relative to untreated samples. 
 
 
Figure 16: SOD western blot analysis of total cellular proteins isolated from mouse NB2a 
cells treated with a 5 hour stimulation of 200 µl (12 µg/ml) goldfish extracellular fluid.  Lanes 
1-2 are controls, not treated with ECF.  Lanes 3 and 4 are treated with ECF.  Arrows on the left 
denote the positions of biotinylated markers in kDa.  The arrow on the right denotes the position 
of the 34 kDa SOD-1. 
 
Figure 17 illustrates two randomly chosen duplicates of six total independent experiments 
done with the same batch of ECF. 
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Figure 17: Example Duplicates of the Experiment Shown in Figure 16. 
 
 The means of trials 1-6 for the in vitro ECF experiments are illustrated in Figure 
18.  The figure shows that there is about a 4-fold increase in the cellular titers of SOD 
protein induced by the 5 hour incubation with ECF.  Error bars denote standard deviation, 
and a statistical analysis was also performed using the two-tailed student T-test in 
Microsoft Excel.  This analysis indicated that the ability of goldfish ECF to upregulate 
SOD in mouse NB2a cells was significant (p = 0.007). 
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Figure 18:  Statistical Analysis of Six In Vitro ECF EPN Experiments.  Error bars denote 
standard deviation.  Asterisks denote the two histobars to obtain the p value. 
 
 
 Since ECF contains a variety of components, this preliminary data did not directly 
show that the EPN component of ECF was responsible for our observed SOD 
upregulation.  Since ECF contains EPN cleavage products, it is possible that the presence 
of 8933 in the ECF was responsible for our observed upregulation.  To address this issue, 
microdialysis was performed on ECF to remove all components less than 8,000 daltons.  
The MW of 8933 is 1149 daltons (Shashoua et al., 2001).  Therefore, 200 µl of ECF was 
put in a microdialyzer system with a membrane pore size of 8,000 daltons.  This would 
remove any small peptides and molecules present in the ECF, while retaining the higher 
molecular weight components, such as full-length EPN at 37,000 and 31,000 daltons.  
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Figure 19:  Statistical Analysis of Four In Vitro Microdialysis Experiments.  Error bars denote 
standard deviation. 
 
Figure 19 illustrates the results of the 4 trials of the microdialysis experiment.  
There is only a slight decrease (not significantly different, p = 0.116) in SOD protein 
levels in the dialyzed ECF (right histobars) compared to the non-dialyzed ECF (middle 
histobars).  Thus, peptide 8933 does not appear to be responsible for this activity because 
manufacturer’s data indicates sample clearance is complete by 20 minutes in this 
microdialyzer unit, and we dialyzed overnight.  This analysis indicated that dialyzed ECF 
was as active as non-dialyzed.  Therefore, it appears that the higher molecular weight 
components of ECF (including full-length EPN) do indeed contribute to the up-regulation 
of SOD seen previously in this section of the thesis. 
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DISCUSSION 
 
 The data from this thesis demonstrate several components of ependymin’s 
mechanism of action.  The first part of this thesis tested whether the mitogen-activated 
protein kinase (MAPK) pathway was involved in CMX-8933’s role in upregulating SOD.  
Previous inhibition experiments in our lab showed that CMX-8933 activates transcription 
factor AP-1 using this MAPK pathway (Hasson, 1998; Adams et al., 2003), so we 
hypothesized that this pathway may upregulate SOD.  We chose three components of this 
pathway to test.  Calphostin-C is a cell-permeable highly specific inhibitor of the PKC 
family of proteins.  For PKC, its 50% inhibition concentration (IC50) is 50 nM (for a 
review, see: Tamaoki and Nakano, 1990).  GEN is a highly specific inhibitor of the PTK, 
with an IC50 of 2.6 µM (Akiyama et al., 1987; Platanias and Colamonici, 1992).  PD 
selectively blocks the activity of MEK-type mitogen-activated protein kinase kinase 
(MAPKK) in vitro and in intact cells (Dudley et al., 1995).  The IC50 for PD is 2 µM.   
Finally, the last inhibitor used in this thesis, PDTC, is a potent inhibitor of NF-κB 
activation, and has an IC50 = 100 µM (Schreck et al., 1992; Tsai et al., 1996).  The 
inhibition experiments in Figure 5 illustrate that inhibition of pathway members PKC, 
PTK and MEKK, completely blocks CMX-8933’s induced SOD signal, while inhibition 
of NF-κB had no effect on SOD signal.  So indeed the MAPK pathway appears to be 
involved in SOD’s upregulation.  Future experiments to be done to further these pathway 
findings are to test whether the CMX-8933/MAPK upregulation of SOD is dependent on 
the simultaneous upregulation of AP-1.  This could be done by using a new AP-1 
inhibitor to “knock out” AP-1 (Palanki et al., 2000).  In addition, one could utilize 
 58
specific kinase/substrate assays to determine which specific components of the PKC, 
PTK and MEKK families are involved in SOD upregulation. 
 The second portion of this thesis used RT-PCR to test whether rat primary cortical 
cells treated with CMX-8933 increase the cellular mRNA titers of known translational 
factors.  Such a finding would help to solidify evidence of EPN’s role in neuronal 
growth.  Figures 8-13 illustrate that treatment of rat primary cortical cultures with 10 
ng/ml  CMX-8933 for 12 hours, increases the mRNA’s for ribosomal proteins R-S12 (12 
fold average, p = 0.02), R-L19 (9 fold average, p = 0.048), as well one elongation factor, 
EF –2 (11 fold average, p = 0.045), relative to the control.  Future experiments on this 
theme could continue RT-PCR for other translation candidates observed from the array 
(Parikh, 2003), such as L-11 and S-19, which all gave moderately increased signals on 
the array.  In addition, through inhibition experiments, one could test whether the MAPK 
pathway is also responsible for these ribosomal protein upregulations.  Immunoblots 
could determine whether ribosomal proteins are upregulated coordinately with their 
mRNAs.  And finally, since all known growth factors increase protein synthesis, a 
comparison study could be done to compare the types of protein synthesis factors up-
regulated by NGF for example versus EPN, to test the uniqueness of EPN as a NTF. 
The last portion of this thesis explored the mechanism of action of full-length 
EPN to compare it to our previous data on the mechanism of action of EPN protease 
cleavage product CMX-8933.  CMX-8933 represents a naturally cleaved product of full-
length EPN.  It exists extra-cellularly and may interact with a specific cell surface 
receptor to initiate a cascade of biochemical steps leading to AP-1 up-regulation, and 
ultimately to SOD up-regulation.  Figures 14 and 15 demonstrate that our method for 
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extracting the ECF of goldfish brains leaves significant amounts of full-length EPN 
present.  Figures 16-18 show that treatment of mouse NB2a neuronal cells with a 200 µl 
dose of ECF for 5 hours induces an average 4 fold (p = 0.007) upregulation of SOD.  
However, ECF is a complex fluid, also known to contain EPN cleavage product 8933, 
which by itself can upregulate SOD.  To determine whether the ECF-induced 
upregulation of SOD resulted from low MW ECF components (including 8933), 
microdialysis was performed using a membrane with a MWCO of 8,000 daltons to 
eliminate smaller components of the ECF.  Figure 19 illustrates that the higher molecular 
weight components, including full-length EPN, are responsible for nearly the entire SOD 
signal.  Therefore, from these initial findings it is hypothesized that full length EPN can 
interact with EPN receptor, like CMX-8933, to elicit a signal transduction response that 
upregulates SOD.  Future experiments could include immuno-purification of EPN to 
determine if that component was responsible for the observed high MW ECF result, or 
the injection of a variety of protease inhibitors into goldfish brain ECF to try to diminish 
the formation of CMX-8933 and see if the same results occur with the up-regulation of 
SOD. 
Overall, the study presented here provides evidence to further understand the 
mechanism of action of both full-length ependymin as well as its cleavage peptide CMX-
8933.  Future experiments will need to be done to extend this understanding, including 
experiments to isolate and characterize the specific cell surface receptor(s), and 
investigating other signal trasduction pathways.  Even though this particular study 
focused only on the upregulation of SOD, this enzyme alone is not enough to alleviate the 
destructive neuronal death following such occurrences as stroke.  At least two other 
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important enzymes play a key role in keeping oxidative stress at safe levels in the cells.  
Catalase and GPX breakdown the H2O2 generated by SOD.  However, because this latter 
H2O2 breakdown reaction is so quick, it is not clear yet whether their titers must be 
increased to maintain safe oxidative stress levels.  Previous experiments in our lab have 
shown that CMX-8933 increases CAT and GPX (Armistead, 2001), however more 
studies on full-length EPN could further strengthen this finding.   
 In conclusion, the data in this thesis are consistent with our hypothesized 
mechanism of action of full-length EPN and CMX-8933.  Both increase the cellular titers 
of the antioxidant enzyme SOD.  CMX-8933 increases the mRNAs that participate in 
neuronal growth, as part of EPN’s known role as a NTF.  EPN and the peptide mimetic 
CMX-8933 may potentially be used for future treatments of neuronal degenerative 
diseases to help reduce the harmful damage caused by dangerous oxiradicals. 
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